…with MAPS PBC teammates and two documentary filmmakers (front center is Lucy Walker, director of the Netflix special on Michael Pollan’s How to Change Your Mind… more to come).
And now, the second phase 3 FDA trial has successfully completed:
"• Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023
• No serious adverse events observed in the MDMA group
• If approved, MAPS PBC’s MDMA-assisted therapy could be the first psychedelic-assisted therapy used to treat a mental health condition
• In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color"
Leave a Reply to John Thompson 2 Cancel reply